Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Susan, Gallipoli"'
Publikováno v:
The Journal of Sexual Medicine. 10:2465-2476
Introduction. Sexual dysfunction is common in major depressive disorder (MDD), and many serotonergic antide- pressants adversely affect sexual function. Vilazodone, a novel serotonin (5-HT) reuptake inhibitor and 5-HT1A partial agonist approved for M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2035efc14eac7e300cfeb0df9fe56c28
https://doi.org/10.1111/jsm.12004
https://doi.org/10.1111/jsm.12004
Autor:
Michael, Liebowitz, Harry A, Croft, Daniel K, Kajdasz, Heidi, Whalen, Susan, Gallipoli, Maria, Athanasiou, Carol R, Reed
Publikováno v:
Psychopharmacology bulletin. 44(3)
Vilazodone is a selective serotonin reuptake inhibitor and 5-HTPooled data from two 8-week, double-blind studies of vilazodone (n = 436) vs placebo (n = 433) and data from one 52-week, open-label study (n = 616, vilazodone only) were analyzed. Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e7e3ff428b387ee2493b415dea55147d
https://pubmed.ncbi.nlm.nih.gov/27738360
https://pubmed.ncbi.nlm.nih.gov/27738360
Autor:
Susan Gallipoli, Heidi Whalen, Michael E. Thase, Carol R. Reed, Maria Athanasiou, Daniel K. Kajdasz
Publikováno v:
Current Medical Research and Opinion. 28:27-39
Vilazodone is a novel serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder (MDD). This evaluation presents side-by-side efficacy data from two randomized, double-blind, placebo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4d608aa9465928ebb719fe5f72a2d0e
https://doi.org/10.1185/03007995.2011.628303
https://doi.org/10.1185/03007995.2011.628303
Autor:
Art Wamil, Susan Gallipoli, Donald S. Robinson, Carol R. Reed, Heidi Whalen, Daniel K. Kajdasz
Publikováno v:
Journal of Clinical Psychopharmacology. 31:643-646
Vilazodone, a selective serotonin (5-HT) reuptake inhibitor and 5-HT(1A) receptor partial agonist, was efficacious in two 8-week placebo-controlled studies in adults with major depressive disorder. This open-label, multicenter study assessed the long
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b62837391288ae3beeb12fa94ed5a7f2
https://doi.org/10.1097/jcp.0b013e31822c6741
https://doi.org/10.1097/jcp.0b013e31822c6741
Autor:
Arif Ullah Khan, Carol R. Reed, Daniel K. Kajdasz, Susan Gallipoli, Donald S. Robinson, Andrew J. Cutler, Heidi Whalen, Maria Athanasiou
Publikováno v:
The Journal of Clinical Psychiatry. 72:441-447
Objective To evaluate the efficacy, and further establish the safety profile, of oral once-daily vilazodone, a potent and selective serotonin 1A receptor partial agonist and reuptake inhibitor, in the treatment of major depressive disorder (MDD). Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c20dd3d1ba3b676e959a8a8edbc7965
https://doi.org/10.4088/jcp.10m06596
https://doi.org/10.4088/jcp.10m06596
Autor:
Marijke H. Adams, James Longstreth, Susan Gallipoli, Michael D Thorn, John Edwards, Ramesh Boinpally, Vasi Sperry
Publikováno v:
International journal of clinical pharmacology and therapeutics. 51(6)
OBJECTIVE: Vilazodone is a potent serotonin reuptake inhibitor and 5-HT1A receptor partial agonist approved for the treatment of major depressive disorder (MDD) in adults. The effect of clinical and supratherapeutic doses of vilazodone on cardiac rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8f1cea1aca93a4bc0b13ace121226b1
https://pubmed.ncbi.nlm.nih.gov/23611569
https://pubmed.ncbi.nlm.nih.gov/23611569
Autor:
Carol R. Reed, Daniel K. Kajdasz, Heidi Whalen, Maria C. Athanasiou, Susan Gallipoli, Michael E. Thase
Publikováno v:
Current Medical Research & Opinion; Jan2012, Vol. 28 Issue 1, p27-39, 13p